Yumin Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1553698/publications.pdf

Version: 2024-02-01

38	549	840776 11	713466 21
papers	citations	h-index	g-index

41	41	41	673
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	miR-196b-5pâ€“mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4347-4357.	7.1	95
2	Long Noncoding RNA Expression Profiles of Lung Adenocarcinoma Ascertained by Microarray Analysis. PLoS ONE, 2014, 9, e104044.	2.5	78
3	Low Expression LncRNA TUBA4B is a Poor Predictor of Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer. Pathology and Oncology Research, 2017, 23, 265-270.	1.9	32
4	lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma. Cancer Management and Research, 2018, Volume 10, 4257-4266.	1.9	31
5	LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis. Medical Oncology, 2014, 31, 137.	2.5	26
6	Distribution and reference interval establishment of neutralâ€toâ€lymphocyte ratio (NLR), lymphocyteâ€toâ€monocyte ratio (LMR), and plateletâ€toâ€lymphocyte ratio (PLR) in Chinese healthy adults. Journal of Clinical Laboratory Analysis, 2021, 35, e23935.	2.1	24
7	LncRNA LINC01512 Promotes the Progression and Enhances Oncogenic Ability of Lung Adenocarcinoma. Journal of Cellular Biochemistry, 2017, 118, 3102-3110.	2.6	20
8	Detection and Analysis of Wnt Pathway Related lncRNAs Expression Profile in Lung Adenocarcinoma. Pathology and Oncology Research, 2016, 22, 609-615.	1.9	18
9	Detection of long-chain non-encoding RNA differential expression in non-small cell lung cancer by microarray analysis and preliminary verification. Molecular Medicine Reports, 2015, 11, 1925-1932.	2.4	17
10	Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. Journal of Clinical Laboratory Analysis, 2017, 31, e22106.	2.1	16
11	Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. BioMed Research International, 2017, 2017, 1-14.	1.9	13
12	Reduced Vitamin D Levels are Associated with Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke . Clinical Interventions in Aging, 2019, Volume 14, 2305-2314.	2.9	12
13	CircRAPGEF5 Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the miR-1236-3p/ZEB1 Axis and Serves as a Potential Biomarker. International Journal of Biological Sciences, 2022, 18, 2116-2131.	6.4	12
14	Differential expression and analysis of extrachromosomal circular DNAs as serum biomarkers in lung adenocarcinoma. Journal of Clinical Laboratory Analysis, 2022, 36, e24425.	2.1	12
15	Identification of dyslipidemia as a risk factor for sudden sensorineural hearing loss: A multicenter caseâ€control study. Journal of Clinical Laboratory Analysis, 2021, 35, e24067.	2.1	11
16	Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression. Oncology Letters, 2014, 8, 813-818.	1.8	10
17	Low expression lncRNA RPLP0P2 is associated with poor prognosis and decreased cell proliferation and adhesion ability in lung adenocarcinoma. Oncology Reports, 2016, 36, 1665-1671.	2.6	10
18	Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer. Oncology Letters, 2017, 14, 5046-5050.	1.8	10

#	Article	IF	Citations
19	Analysis of lncRNA UCA1â€related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma. Journal of Clinical Laboratory Analysis, 2020, 34, e23312.	2.1	9
20	Constructing a 10â€core genes panel for diagnosis of pediatric sepsis. Journal of Clinical Laboratory Analysis, 2021, 35, e23680.	2.1	9
21	Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma. Cancer Cell International, 2021, 21, 505.	4.1	9
22	Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion. Journal of Clinical Laboratory Analysis, 2018, 32, e22576.	2.1	8
23	Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. Genes, 2018, 9, 32.	2.4	7
24	Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with nonâ€“smallâ€cell lung cancer. Journal of Clinical Laboratory Analysis, 2019, 33, e22943.	2.1	7
25	A nomogram prediction of pressure injury in critical ill patients: A retrospective cohort study. International Wound Journal, 2022, 19, 826-833.	2.9	7
26	Super enhancerâ€LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. Journal of Clinical Laboratory Analysis, 2022, 36, e24460.	2.1	7
27	ADH1C Facilitates Cisplatin Resistance of Lung Adenocarcinoma Cells. DNA and Cell Biology, 2022, 41, 631-640.	1.9	6
28	Critically Ill vs. Non-Critically Ill Patients With COVID-19ÂPneumonia: Clinical Features, Laboratory Findings, and Prediction. Frontiers in Cellular and Infection Microbiology, 2021, 11, 550456.	3.9	5
29	LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13. Cell Cycle, 2022, , 1-15.	2.6	5
30	Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion. Journal of Clinical Laboratory Analysis, 2020, 34, e23091.	2.1	4
31	High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. PeerJ, 2021, 9, e11697.	2.0	4
32	Low expression of PRKCDBP promoted cisplatin resistance in lung adenocarcinoma by DNMT1 and TNFâ€Î±. Oncology Reports, 2020, 44, 1616-1626.	2.6	4
33	LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1295-1311.	2.5	4
34	Integrated Analysis of Multi-Omics Data to Identify Prognostic Genes for Pancreatic Cancer. DNA and Cell Biology, 2022, , .	1.9	2
35	Lowâ€level EFCAB1 promoted progress by upregulated DNMT3B and could be as a potential biomarker in lung adenocarcinoma. Journal of Clinical Laboratory Analysis, 2022, 36, e24166.	2.1	2
36	lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma. BioMed Research International, 2020, 2020, 1-18.	1.9	1

#	Article	IF	Citations
37	Lowâ€level gastrokine 2 promoted progress of NSCLC and as a potential biomarker. Journal of Clinical Laboratory Analysis, 2022, 36, e24213.	2.1	1
38	Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C. Archives of Iranian Medicine, 2013, 16, 74-7.	0.6	1